Back to top
more

Cencora, Inc. (COR)

(Delayed Data from NYSE)

$222.00 USD

222.00
943,622

-0.42 (-0.19%)

Updated Jul 11, 2024 04:00 PM ET

After-Market: $222.04 +0.04 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

BD (BDX), Camtech Health Unite to Aid Cervical Cancer Screening

BD (BDX) collaborates with Camtech Health to improve the rate of cervical cancer screening in Singapore by offering women an option to self-collect samples in the privacy of their own homes.

Lantheus (LNTH) Q4 Earnings Surpass Estimates, Gross Margin Up

Lantheus' (LNTH) robust segmental revenues drive its fourth-quarter performance.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio for Now

Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.

Teleflex (TFX) Q4 Earnings Top Estimates, Operating Margin Falls

Teleflex (TFX) surpasses earnings and revenue estimates in the fourth quarter of 2023.

Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands

Veracyte's (VCYT) fourth-quarter 2023 performance reflects solid financial discipline and the strength of the Decipher Prostate and Afirma tests.

ICON (ICLR) Q4 Earnings Surpass Estimates, Margins Expand

ICON's (ICLR) solid performance in the fourth quarter reflects continued market leadership across customer segments it serves.

Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status

Better Therapeutics' (BTTX) novel CBT platform attains the FDA's breakthrough device designation to improve patient care in the treatment of liver and metabolic diseases.

Nevro's (NVRO) Q4 Earnings and Sales Top Estimates, Margins Up

Nevro's (NVRO) fourth-quarter earnings and revenues surpass their respective consensus estimate. The company incurs a loss in the operating level.

Exact Sciences (EXAS) Q4 Loss Narrows, Revenues Rise Y/Y

Robust revenues from Exact Sciences' (EXAS) Screening and Precision Oncology segments contribute to the fourth-quarter top line.

Glaukos (GKOS) Q4 Earnings Miss Estimates, Revenues Rise Y/Y

Glaukos' (GKOS) fourth-quarter revenues beat estimates as well as gained year over year. Gross margin improve, while higher operating expenses lead to a wider operating loss.

Tandem Diabetes (TNDM) Posts Wider Q4 Loss, Gross Margin Down

Tandem Diabetes (TNDM) reports a higher-than-expected loss in the fourth quarter of 2023.

Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?

Smart Beta ETF report for ONEV

Here's Why You Should Retain Align Technology (ALGN) Stock Now

Investors are optimistic about Align Technology (ALGN) on continued geographic expansion.

Boston Scientific (BSX) Surges 4.6%: Will the Rally Continue?

Boston Scientific (BSX) is benefitting from an impressive gain in MedSurg market share and the strong adoption of WATCHMAN FLX.

Avanos (AVNS) Q4 Earnings Lag Estimates, Margins Contract

Despite strength in Avanos' (AVNS) Digestive Health segment, its overall fourth-quarter results reflect soft performances.

Globus Medical (GMED) Q4 Earnings Surpass, Margins Down

Globus Medical's (GMED) fourth-quarter 2023 performance benefits from innovative launches across its product groups.

Medtronic (MDT) Q3 Earnings Beat Estimates, 2024 View Up

Medtronic's (MDT) third-quarter organic growth reflects broad strength across businesses and geographies.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

Investors are optimistic about ResMed's (RMD) increased adoption of AirSense10 and AirSense11 devices.

Thermo Fisher (TMO) Introduces Dionex Inuvion IC system

Thermo Fisher's (TMO) Dionex Inuvion system helps labs operate more effectively by providing simple, adjustable workflows and a small footprint.

IDEXX (IDXX) Unveils Pet Owner Engagement Software Solution

IDEXX's (IDXX) Vello software is an intuitive solution designed specifically for practice management software that enables practitioners to interact with pet owners before and after visits.

PacBio (PACB) Q4 Earnings Beat, Adjusted Gross Margin Down

PacBio (PACB) witnesses strong revenue growth in the fourth quarter, partly aided by customers' continued product transition to the Revio system.

AMN Healthcare (AMN) Q4 Earnings and Revenues Beat Estimates

AMN Healthcare's (AMN) dismal results in the majority of its segments led to a soft overall fourth-quarter performance.

ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 (Revised)

ResMed's (RMD) new AirCurve11 series incorporates MyAir and AirView digital health apps to provide maximum comfort and support during therapy.

Bio-Rad (BIO) Q4 Earnings Beat, Revenues Miss, Margins Down

Bio-Rad (BIO) continues to experience weak demand for Life Science products in China.